Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02505165
Other study ID # NR014248
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 19, 2015
Est. completion date February 1, 2022

Study information

Verified date April 2022
Source Children's Hospital Medical Center, Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the efficacy of a clinic-based intervention designed to reduce illness uncertainty for parents of children who have been recently diagnosed with cancer.


Description:

The proposed trial will test the efficacy of the parent-focused clinic-based Parent Uncertainty Management Intervention (PUMI) to improve the outcomes of children newly diagnosed with cancer and their parents. Participants will be randomly assigned to receive equivalent doses of either the PUMI or an Education/Support (ESO) group. Theoretically driven by Mishel's model of illness uncertainty, the PUMI will teach parents about uncertainty prevention and management through the use of medically-specific communication, information management, and problem-solving skills via in-clinic sessions and an online portal. Parents and children will complete measures online at baseline, 1-week, and 3-, 6-, and 12-month follow-ups.


Recruitment information / eligibility

Status Completed
Enrollment 279
Est. completion date February 1, 2022
Est. primary completion date April 22, 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - The child has been diagnosed with leukemia or lymphoma, malignant solid tumor, or malignant brain tumor - The child is being treated for cancer and returning to the medical center (CCHMC or OUHSC). - The child is 18 years of age or younger - Recruitment occurs within 2-12 weeks post diagnosis - The parent is responsible for care and is willing to give consent and participate - The child is willing to give assent or consent and participate (only for children 8 years old and older) - The parent gives patient permission to participate. - Parent is fluent in English Exclusion Criteria: - The child is experiencing an imminent medical crisis necessitating significant medical intervention - The child with cancer is determined to be in the terminal phase of illness and/or is receiving end of life care - The diagnosis is determined to be a relapse or a second malignancy - The parent is currently being treated for a serious psychiatric disorder, or, evidences mental retardation - The parent is younger than 18 years of age - The parent is not English speaking - The parent is unwilling to give written permission for child participation - If the patient's treatment visit schedule is too infrequent to meet the study visit timeline requirements

Study Design


Intervention

Behavioral:
IMPACT
• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
Other:
ESO
This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.

Locations

Country Name City State
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Dayton Children's Hospital Dayton Ohio
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma

Sponsors (4)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati Dayton Children's Hospital, Oklahoma State University, University of Oklahoma

Country where clinical trial is conducted

United States, 

References & Publications (5)

Basile NL, Chardon ML, Peugh J, Edwards CS, Szulczewski L, Morrison CF, Nagarajan R, El-Sheikh A, Chaney JM, Pai ALH, Mullins LL. Relationship Between Caregiver Uncertainty, Problem-Solving, and Psychological Adjustment in Pediatric Cancer. J Pediatr Psyc — View Citation

Marsolo K, Shuman W, Nix J, Morrison CF, Mullins LL, Pai AL. Reducing Parental Uncertainty Around Childhood Cancer: Implementation Decisions and Design Trade-Offs in Developing an Electronic Health Record-Linked Mobile App. JMIR Res Protoc. 2017 Jun 26;6( — View Citation

Morrison CF, Szulczewski L, Strahlendorf LF, Lane JB, Mullins LL, Pai AL. Designing Technology to Address Parent Uncertainty in Childhood Cancer. ANS Adv Nurs Sci. 2016 Jan-Mar;39(1):15-25. doi: 10.1097/ANS.0000000000000100. — View Citation

Sharkey CM, Schepers SA, Drake S, Pai ALH, Mullins LL, Grootenhuis MA. Psychosocial Risk Profiles Among American and Dutch Families Affected by Pediatric Cancer. J Pediatr Psychol. 2020 May 1;45(4):463-473. doi: 10.1093/jpepsy/jsaa012. — View Citation

Szulczewski L, Mullins LL, Bidwell SL, Eddington AR, Pai ALH. Meta-Analysis: Caregiver and Youth Uncertainty in Pediatric Chronic Illness. J Pediatr Psychol. 2017 May 1;42(4):395-421. doi: 10.1093/jpepsy/jsw097. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Psychosocial Functioning as assessed by the global severity index (GSI) of the symptom checklist 90. indicator of global psychological symptoms Change in (global severity index) GSI score from baseline to 1-week post-intervention
Primary Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90. indicator of global psychological symptoms Change in GSI score from baseline to 3-month post-intervention
Primary Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90. indicator of global psychological symptoms Change in GSI score from baseline to 6-month post-intervention
Primary Psychosocial Functioning as assessed by the global severity index of the symptom checklist 90. indicator of global psychological symptoms Change in GSI score from baseline to 12-month post-intervention
Secondary Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) Measure of caregiver post-traumatic stress symptoms Change in IES-R total score score from baseline to 1-week post-intervention
Secondary Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) Measure of caregiver post-traumatic stress symptoms Change in IES-R total score score from baseline to 3-month post-intervention
Secondary Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) Measure of caregiver post-traumatic stress symptoms Change in IES-R total score score from baseline to 6-month post-intervention
Secondary Post-Traumatic Stress Symptoms as assessed by the Impact of Events Scale-Revised (IES-R) Measure of caregiver post-traumatic stress symptoms Change in IES-R total score score from baseline to 12-month post-intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1